T cell senescence and CAR-T cell exhaustion in hematological malignancies

被引：191
作者：
Kasakovski, Dimitri [1 ,2 ]
Xu, Ling [1 ,3 ]
Li, Yangqiu [1 ,3 ]
机构：
[1] Jinan Univ, Key Lab Regenerat Med, Minist Educ, Inst Hematol,Sch Med, Guangzhou 510632, Guangdong, Peoples R China
[2] Ruhr Univ Bochum, Dept Anat & Mol Embryol, Inst Anat, D-44801 Bochum, Germany
[3] Jinan Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2018年 / 11卷
基金：
中国国家自然科学基金;
关键词：
T cells; Senescence; Hematological malignancy; T cell activation; CAR-T cells; UMBILICAL-CORD BLOOD; IMMUNE MODULATION; REPLICATIVE SENESCENCE; REGENERATIVE THERAPY; 4-1BB COSTIMULATION; ENVIRONMENTAL CUES; TUMOR-IMMUNITY; CANCER; TRANSPLANTATION; INDUCTION;
D O I：
10.1186/s13045-018-0629-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell senescence has been recognized to play an immunosuppressive role in the aging population and cancer patients. Strategies dedicated to preventing or reversing replicative and premature T cell senescence are required to increase the lifespan of human beings and to reduce the morbidity from cancer. In addition, overcoming the T cell terminal differentiation or senescence from lymphoma and leukemia patients is a promising approach to enhance the effectiveness of adoptive cellular immunotherapy (ACT). Chimeric antigen receptor T (CAR-T) cell and T cell receptor-engineered T (TCR-T) cell therapy highly rely on functionally active T cells. However, the mechanisms which drive T cell senescence remain unclear and controversial. In this review, we describe recent progress for restoration of T cell homeostasis from age-related senescence as well as recovery of T cell activation in hematological malignancies.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] T cell senescence and CAR-T cell exhaustion in hematological malignancies
    Dimitri Kasakovski
    Ling Xu
    Yangqiu Li
    Journal of Hematology & Oncology, 11
  • [2] T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
    Tang, Lu
    Zhang, Yinqiang
    Hu, Yu
    Mei, Heng
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [3] PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
    Singh, Shashi B.
    Bhandari, Sadikshya
    Siwakoti, Shisir
    Kumar, Manoj
    Singh, Rajshree
    Bhusal, Subarna
    Sharma, Karuna
    Bhandari, Samikshya
    Khanal, Kishor
    MOLECULAR IMAGING, 2024, 23
  • [4] CAR-T Cell Therapy for T-Cell Malignancies
    Testa, Ugo
    Chiusolo, Patrizia
    Pelosi, Elvira
    Castelli, Germana
    Leone, Giuseppe
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
  • [5] Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
    Xiong, Dian
    Yu, Haijun
    Sun, Zhi-Jun
    ACTA PHARMACEUTICA SINICA B, 2024, 14 (08) : 3416 - 3431
  • [6] Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
    Gumber, Diana
    Wang, Leo D.
    EBIOMEDICINE, 2022, 77
  • [7] Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
    Cao, Xinping
    Jin, Xin
    Zhang, Xiaomei
    Utsav, Paudel
    Zhang, Yi
    Guo, Ruiting
    Lu, Wenyi
    Zhao, Mingfeng
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (03) : 184 - 211
  • [8] Resistance and recurrence of malignancies after CAR-T cell therapy
    Zeng, Wanying
    Zhang, Pumin
    EXPERIMENTAL CELL RESEARCH, 2022, 410 (02)
  • [9] CAR T-Cell Therapy in Hematological Malignancies
    Haslauer, Theresa
    Greil, Richard
    Zaborsky, Nadja
    Geisberger, Roland
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [10] T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies
    Maurer, Katie
    Jacobson, Caron A.
    LEUKEMIA & LYMPHOMA, 2025,
12345